<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01226043</url>
  </required_header>
  <id_info>
    <org_study_id>LANTU_L_05191</org_study_id>
    <secondary_id>U1111-1116-3054</secondary_id>
    <nct_id>NCT01226043</nct_id>
  </id_info>
  <brief_title>Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus</brief_title>
  <acronym>Pen Preference</acronym>
  <official_title>An Open Label Randomized Multicenter Study to Assess Patient Preference for and Evaluate Clinical Benefit of Insulin Glargine (Lantus®) SoloSTAR® Pen Versus Conventional Vial/Syringe Method of Insulin Glargine (Lantus®) Injection Therapy in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary Objective:

      To assess patient preference for Lantus SoloSTAR pen versus Lantus vial and syringe at the
      end of Crossover Phase (Week 4) in patients with type 2 diabetes mellitus (T2DM)

      Secondary Objectives:

      To compare Lantus SoloSTAR pen versus Lantus vial and syringe with regard to the following
      parameters:

      Randomization/Crossover phase:

        -  Healthcare professional's (HCP) recommendation for Lantus SoloSTAR pen versus Lantus
           vial and syringe

      Re-randomization phase:

        -  Change in Fasting Plasma Glucose (FPG) from week 4 to week 10

        -  Percentage of patients achieving FPG&lt;110 mg/dL at week 10

        -  Change in Lantus dose injected per day (U) from week 4 to week 10

      Observational phase:

        -  Percentage of patients achieving glycosylated hemoglobin (HbA1c) goal (&lt;7%) at week 40

        -  Time to first observation of HbA1c&lt;7% during the observational phase

        -  Percentage of patients who discontinue Investigational Product (IP) during the
           observational phase due to dissatisfaction with their current device

      All phases:

        -  Percentage of patients who discontinue IP during each phase of the study

        -  Safety assessment such as occurrence of hypoglycemic events (HE) and adverse events (AE)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consisted of a 1 week Screening Phase, a 4-week Randomization/Crossover Phase, a
      6-week Re-randomization Phase, followed by a 30 week Observational Phase.

      The total duration of study participation was up to 41 weeks with a total treatment duration
      of up to 40 weeks of Lantus exposure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Overall Preference</measure>
    <time_frame>At week 4 (end of crossover phase)</time_frame>
    <description>The patient preference was assessed in terms of the difference in scores obtained from the overall preference question 14d &quot;Overall, what is your level of preference for each of the insulin delivery systems?&quot;
5 points scale: from 1=Not preferred to 5= Always preferred</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Preference Composite Score</measure>
    <time_frame>At week 4 (end of crossover phase)</time_frame>
    <description>The patient preference composite score was the sum of the scores of the 3 following individual preference questions from the Patient preference Questionnaire:
Question 14a: How strongly do you prefer each of these insulin delivery systems to control blood sugar?
Question 14b: If using insulin for the first time, how strongly would you prefer using each of these delivery systems to overcome reluctance to use insulin?
Question 14c: How strongly would you prefer each insulin delivery system for long-term use?
Each individual question scored from 1 to 5. The lowest score 1 indicated 'Not Preferred' and the highest score 5 indicated 'Always Preferred'. Therefore the total range of the composite score was 3 to 15.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare Professional's (HCP) Recommendation</measure>
    <time_frame>At week 4 (end of crossover phase)</time_frame>
    <description>The overall recommendation score was obtained from the question 20d of the Healthcare Professional Questionnaire: &quot;Overall, how strongly would you recommend each of the insulin delivery systems for your patients?&quot;
5 points scale: from 1= Not Recommended to 5= Recommended</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose (FPG)</measure>
    <time_frame>From week 4 (baseline for re-randomization phase) to week 10 (end of re-randomization phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving Fasting Plasma Glucose (FPG) &lt;110 mg/dL</measure>
    <time_frame>At week 10 (end of re-randomization phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Lantus Dose Injected Per Day</measure>
    <time_frame>From week 4 (baseline for re-randomization phase) to week 10 (end of re-randomization phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving HbA1c Goal</measure>
    <time_frame>measured at week 40 or at study discontinuation</time_frame>
    <description>Percentage of patients achieving HbA1c &lt; 7% at Week 40 (end of the observational phase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Observation of HbA1c &lt;7%</measure>
    <time_frame>From week 10 to week 40 (observational phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Discontinued Investigational Product (IP) During the Crossover Phase</measure>
    <time_frame>From baseline to week 4 (crossover phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Discontinued Investigational Product During the Re-randomization Phase</measure>
    <time_frame>From week 4 to week 10 (re-randomization phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Discontinued Investigational Product During the Observational Phase</measure>
    <time_frame>From week 10 to week 40 (observational phase)</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Patients With Hypoglycemic Events</measure>
    <time_frame>each study phase (crossover, re-randomization, observational) up to 40 weeks</time_frame>
    <description>The hypoglycemic event was to be recorded on the electronic case report form hypoglycemia page and had to fit in one of the following categories: Mild-to-moderate hypoglycemia (36 mg/dL ≤ Self Monitored Blood Glucose (SMBG) &lt;70mg/dL), Severe hypoglycemia (assistance of another person is required, and either a recorded SMBG &lt;36 mg/dL, or treatment with oral carbohydrates, intravenous glucose or glucagon with prompt response) or Hypoglycemia symptoms with or without SMBG values with a documented SMBG &gt;70 mg/dL, or no recorded SMBG value. Only hypoglycemia events associated with coma, loss of consciousness or seizure were considered serious adverse event (SAEs).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">405</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Lantus (insulin glargine) vial &amp; syringe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mL vial, 1000 U per vial for subcutaneous administration once a day. Starting dose will be 0.2 Unit per kilogram of body weight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lantus (insulin glargine) SoloSTAR pen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 mL SoloSTAR pre-filled disposable insulin delivery device (pen), 300 U per device for subcutaneous administration once a day. Starting dose will be 0.2 Unit per kilogram of body weight.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <description>Pharmaceutical form: solution for injection
Route of administration: subcutaneous</description>
    <arm_group_label>Lantus (insulin glargine) vial &amp; syringe</arm_group_label>
    <arm_group_label>Lantus (insulin glargine) SoloSTAR pen</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Patients with a confirmed diagnosis of type 2 diabetes mellitus who were treated with any
        combination of 2 or 3 oral antidiabetic drugs (OADs) at a stable dose for the preceding 3
        months, including but not limited to:

          -  Metformin + sulfonylurea + thiazolidinedione (Pioglitazone)

          -  Metformin + sulfonylurea

          -  Metformin + thiazolidinedione (Pioglitazone)

          -  Metformin + dipeptidyl peptidase (DPPIV)

        And for whom the Investigator/treating physician had decided that basal insulin was
        appropriate.

        Patients who had signed an Informed Consent Form and Health Insurance Portability and
        Accountability Act (HIPAA) Authorization Form

        Exclusion criteria:

          -  Patients less than 18 years or greater than 85 years of age (ie, have not reached the
             age of 86 at the screening visit)

          -  Patients with a confirmed diagnosis of type 1 diabetes mellitus

          -  Patients who were treated with insulin or who had been treated with insulin in the
             preceding 12 months with the exception of insulin treatment during hospitalization
             (ie, patients who received insulin while hospitalized could be included)

          -  Patients whose screening HbA1c is &lt;7% or &gt;10%

          -  Patients with current addiction or current alcohol / drug abuse

          -  Patients with cardiac status New York Heart Association III-IV

          -  Patients with stroke, myocardial infarction, coronary artery bypass graft,
             percutaneous transluminal coronary angioplasty, or unstable angina pectoris within the
             12 months prior to screening

          -  Patients with a diagnosis of dementia, severe visual or dexterity impairment

          -  Patients with any malignancy within the last 5 years, with the exception of adequately
             treated basal or squamous cell carcinoma of the skin or adequately treated cervical
             carcinoma in situ

          -  Patients with concomitant disease or concomitant medication that could interfere with
             treatment or ability to answer questionnaires

          -  Patients who were unable to self-inject

          -  Patients who were taking or had been treated with Byetta® (exenatide) or other
             Glucagon-Like Peptide-1 agonists within 3 months before screening:

          -  Patients who were pregnant or breastfeeding

          -  Women of childbearing potential not protected by a highly effective contraceptive
             method of birth control (as defined for contraception in the Informed Consent Form and
             /or in a local protocol addendum) and/or who were unwilling or unable to be tested for
             pregnancy

          -  Patients with impaired renal function as shown by serum creatinine ≥1.5 mg/dL for
             males or ≥1.4 mg/dL for females at screening

          -  Patients with clinical evidence of active liver disease, or serum alanine
             aminotransferase (ALT) or aspartate aminotransferase (AST) 2.5 times the upper limit
             of the normal range (ULN)

          -  Patients unlikely to comply with the protocol requirements (eg, illiterate,
             uncooperative, unable to return for scheduled visits, unlikely to complete the study)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2010</study_first_submitted>
  <study_first_submitted_qc>October 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2010</study_first_posted>
  <results_first_submitted>May 3, 2013</results_first_submitted>
  <results_first_submitted_qc>July 29, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 30, 2013</results_first_posted>
  <last_update_submitted>July 30, 2013</last_update_submitted>
  <last_update_submitted_qc>July 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment of patients started on October 26, 2010 and the study was completed on May 7, 2012. Patients were screened in 60 centers in the United States of America, of which 59 centers randomized patients.</recruitment_details>
      <pre_assignment_details>A total 623 patients were screened of whom 405 insulin naïve patients were randomized for the crossover phase. The most common reason for non randomization was glycosylated hemoglobin (HbA1c) value out of range at the screening visit as defined per protocol.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pen (Period 1) / Vial &amp; Syringe (Period 2)</title>
          <description>Crossover phase: patients randomized to the sequence: Lantus SoloSTAR® pen in Period 1 and Lantus vial and syringe in Period 2.</description>
        </group>
        <group group_id="P2">
          <title>Vial &amp;Syringe (Period 1) / Pen (Period 2)</title>
          <description>Crossover phase: patients randomized to the sequence: Lantus vial and syringe in Period 1 and Lantus SoloSTAR pen in Period 2.</description>
        </group>
        <group group_id="P3">
          <title>SoloSTAR® Pen</title>
          <description>Re-randomization phase and the observational phase: patients randomized to Lantus SoloSTAR® pen.</description>
        </group>
        <group group_id="P4">
          <title>Vial and Syringe</title>
          <description>Re-randomization phase and the observational phase: patients randomized to Lantus Vial and Syringe.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>4-week Crossover Phase - Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="202"/>
                <participants group_id="P2" count="203"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>TREATED</title>
              <participants_list>
                <participants group_id="P1" count="202"/>
                <participants group_id="P2" count="200"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="199"/>
                <participants group_id="P2" count="194"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>4-week Crossover Phase - Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="199"/>
                <participants group_id="P2" count="194"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>TREATED</title>
              <participants_list>
                <participants group_id="P1" count="199"/>
                <participants group_id="P2" count="194"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="195">28 patients were not re-randomized to the second phase of the study</participants>
                <participants group_id="P2" count="188">22 patients were not re-randomized to the second phase of the study</participants>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>6-week Re-randomization Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="166"/>
                <participants group_id="P4" count="167"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>TREATED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="165"/>
                <participants group_id="P4" count="165"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="159"/>
                <participants group_id="P4" count="156">3 patients did not enter the observational phase of the study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>completed in error</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>30-week Observational Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="159"/>
                <participants group_id="P4" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>TREATED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="159"/>
                <participants group_id="P4" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="153"/>
                <participants group_id="P4" count="140"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics provided for the population randomized for the first phase of the study: crossover phase.</population>
      <group_list>
        <group group_id="B1">
          <title>Crossover Phase: Pen / Vial &amp; Syringe</title>
          <description>Patients randomized to the sequence: Lantus SoloSTAR pen in Period 1 and Lantus vial and syringe in Period 2 for the 4-week crossover phase.</description>
        </group>
        <group group_id="B2">
          <title>Crossover Phase: Vial &amp; Syringe / Pen</title>
          <description>Patients randomized to the sequence: Lantus vial and syringe in Period 1 and Lantus SoloSTAR pen in Period 2 for the 4-week crossover phase.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="202"/>
            <count group_id="B2" value="203"/>
            <count group_id="B3" value="405"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.7" spread="10.1"/>
                    <measurement group_id="B2" value="58.1" spread="10.9"/>
                    <measurement group_id="B3" value="57.9" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103.80" spread="26.43"/>
                    <measurement group_id="B2" value="98.48" spread="20.75"/>
                    <measurement group_id="B3" value="101.13" spread="23.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.93" spread="7.87"/>
                    <measurement group_id="B2" value="33.73" spread="6.64"/>
                    <measurement group_id="B3" value="34.83" spread="7.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patient Overall Preference</title>
        <description>The patient preference was assessed in terms of the difference in scores obtained from the overall preference question 14d “Overall, what is your level of preference for each of the insulin delivery systems?”
5 points scale: from 1=Not preferred to 5= Always preferred</description>
        <time_frame>At week 4 (end of crossover phase)</time_frame>
        <population>The modified intent-to-treat (mITT) population for the Patient Preference Questionnaire analysis consisted of all randomized patients who received at least one dose of Lantus via both insulin delivery systems and completed the questionnaire at Week 4. This analysis included patients who answered question 14d.</population>
        <group_list>
          <group group_id="O1">
            <title>SoloSTAR® Pen</title>
            <description>Patients using the SoloSTAR® Pen during the crossover phase either at period 1 or at period 2 depending on the sequence allocated by randomization.</description>
          </group>
          <group group_id="O2">
            <title>Vial and Syringe</title>
            <description>Patients using the Vial and Syringe during the crossover phase either at period 1 or at period 2 depending on the sequence allocated by randomization.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Overall Preference</title>
          <description>The patient preference was assessed in terms of the difference in scores obtained from the overall preference question 14d “Overall, what is your level of preference for each of the insulin delivery systems?”
5 points scale: from 1=Not preferred to 5= Always preferred</description>
          <population>The modified intent-to-treat (mITT) population for the Patient Preference Questionnaire analysis consisted of all randomized patients who received at least one dose of Lantus via both insulin delivery systems and completed the questionnaire at Week 4. This analysis included patients who answered question 14d.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="388"/>
                <count group_id="O2" value="388"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.75" spread="4.75" lower_limit="4.65" upper_limit="4.85"/>
                    <measurement group_id="O2" value="2.45" lower_limit="2.35" upper_limit="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis was to determine whether patients have higher preference score for Lantus® SoloSTAR® pen compared to Lantus® vial/syringe. Differences of patient preference score greater than 0.5 were considered clinically meaningful. The power for detecting a true difference of 0.5 considering a standard deviation from 1.6 to 2.5, assuming 130 evaluable patients per arm and a two-sided test at 0.05 significance level ranged from 89% to more than 99%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <method_desc>The last observation carried forward (LOCF) method was applied to impute missing Week 4 overall patient preference values for ANOVA analysis.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.15</ci_lower_limit>
            <ci_upper_limit>2.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Preference Composite Score</title>
        <description>The patient preference composite score was the sum of the scores of the 3 following individual preference questions from the Patient preference Questionnaire:
Question 14a: How strongly do you prefer each of these insulin delivery systems to control blood sugar?
Question 14b: If using insulin for the first time, how strongly would you prefer using each of these delivery systems to overcome reluctance to use insulin?
Question 14c: How strongly would you prefer each insulin delivery system for long-term use?
Each individual question scored from 1 to 5. The lowest score 1 indicated 'Not Preferred' and the highest score 5 indicated 'Always Preferred'. Therefore the total range of the composite score was 3 to 15.</description>
        <time_frame>At week 4 (end of crossover phase)</time_frame>
        <population>The modified intent-to-treat (mITT) population for the Patient Preference Questionnaire analysis consisted of all randomized patients who received at least one dose of Lantus via both insulin delivery systems and completed the questionnaire at Week 4. This analysis included patients who answered to the 3 questions 14a, 14b and 14c.</population>
        <group_list>
          <group group_id="O1">
            <title>SoloSTAR® Pen</title>
            <description>Patients using the SoloSTAR® Pen during the crossover phase either at period 1 or at period 2 depending on the sequence allocated by randomization.</description>
          </group>
          <group group_id="O2">
            <title>Vial and Syringe</title>
            <description>Patients using the Vial and Syringe during the crossover phase either at period 1 or at period 2 depending on the sequence allocated by randomization.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Preference Composite Score</title>
          <description>The patient preference composite score was the sum of the scores of the 3 following individual preference questions from the Patient preference Questionnaire:
Question 14a: How strongly do you prefer each of these insulin delivery systems to control blood sugar?
Question 14b: If using insulin for the first time, how strongly would you prefer using each of these delivery systems to overcome reluctance to use insulin?
Question 14c: How strongly would you prefer each insulin delivery system for long-term use?
Each individual question scored from 1 to 5. The lowest score 1 indicated 'Not Preferred' and the highest score 5 indicated 'Always Preferred'. Therefore the total range of the composite score was 3 to 15.</description>
          <population>The modified intent-to-treat (mITT) population for the Patient Preference Questionnaire analysis consisted of all randomized patients who received at least one dose of Lantus via both insulin delivery systems and completed the questionnaire at Week 4. This analysis included patients who answered to the 3 questions 14a, 14b and 14c.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="384"/>
                <count group_id="O2" value="384"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2" lower_limit="13.88" upper_limit="14.44"/>
                    <measurement group_id="O2" value="7.49" lower_limit="7.21" upper_limit="7.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Healthcare Professional's (HCP) Recommendation</title>
        <description>The overall recommendation score was obtained from the question 20d of the Healthcare Professional Questionnaire: “Overall, how strongly would you recommend each of the insulin delivery systems for your patients?”
5 points scale: from 1= Not Recommended to 5= Recommended</description>
        <time_frame>At week 4 (end of crossover phase)</time_frame>
        <population>The HCP Questionnaire analysis population consisted of HCPs:
who treated at least 1 randomized patient during the crossover phase and this(these) patient(s) received at least one dose of Lantus via both insulin delivery systems during the crossover phase
who completed the HCP Questionnaire.</population>
        <group_list>
          <group group_id="O1">
            <title>SoloSTAR® Pen</title>
            <description>SoloSTAR® Pen used during the crossover phase either at period 1 or at period 2</description>
          </group>
          <group group_id="O2">
            <title>Vial and Syringe</title>
            <description>Vial and Syringe used during the crossover phase either at period 1 or at period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Healthcare Professional's (HCP) Recommendation</title>
          <description>The overall recommendation score was obtained from the question 20d of the Healthcare Professional Questionnaire: “Overall, how strongly would you recommend each of the insulin delivery systems for your patients?”
5 points scale: from 1= Not Recommended to 5= Recommended</description>
          <population>The HCP Questionnaire analysis population consisted of HCPs:
who treated at least 1 randomized patient during the crossover phase and this(these) patient(s) received at least one dose of Lantus via both insulin delivery systems during the crossover phase
who completed the HCP Questionnaire.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="4" upper_limit="5"/>
                    <measurement group_id="O2" value="3.0" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Plasma Glucose (FPG)</title>
        <time_frame>From week 4 (baseline for re-randomization phase) to week 10 (end of re-randomization phase)</time_frame>
        <population>The mITT population for Re-randomization and Observational Phases consisted of all patients who were re-randomized, received at least one dose of Lantus after re-randomization, and had both a re-randomization baseline assessment and at least one post re-randomization assessment of FPG measured during the on-treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>SoloSTAR® Pen</title>
            <description>Patients randomized to SoloSTAR® Pen during the Re-randomization period (Week 4 to Week 10)</description>
          </group>
          <group group_id="O2">
            <title>Vial and Syringe</title>
            <description>Patients randomized to Vial and Syringe during the Re-randomization period (Week 4 to Week 10)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Glucose (FPG)</title>
          <population>The mITT population for Re-randomization and Observational Phases consisted of all patients who were re-randomized, received at least one dose of Lantus after re-randomization, and had both a re-randomization baseline assessment and at least one post re-randomization assessment of FPG measured during the on-treatment period.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.3" spread="2.87"/>
                    <measurement group_id="O2" value="-14.5" spread="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving Fasting Plasma Glucose (FPG) &lt;110 mg/dL</title>
        <time_frame>At week 10 (end of re-randomization phase)</time_frame>
        <population>The mITT population for Re-randomization and Observational Phases consisted of all patients who were re-randomized, received at least one dose of Lantus after re-randomization, and had a re-randomization baseline assessment FPG &gt; or = 110 (week 4) and at least one post re-randomization assessment of FPG.</population>
        <group_list>
          <group group_id="O1">
            <title>SoloSTAR® Pen</title>
            <description>Patients randomized to SoloSTAR® Pen during the Re-randomization period (Week 4 to Week 10)</description>
          </group>
          <group group_id="O2">
            <title>Vial and Syringe</title>
            <description>Patients randomized to Vial and Syringe during the Re-randomization period (Week 4 to Week 10)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving Fasting Plasma Glucose (FPG) &lt;110 mg/dL</title>
          <population>The mITT population for Re-randomization and Observational Phases consisted of all patients who were re-randomized, received at least one dose of Lantus after re-randomization, and had a re-randomization baseline assessment FPG &gt; or = 110 (week 4) and at least one post re-randomization assessment of FPG.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8"/>
                    <measurement group_id="O2" value="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Lantus Dose Injected Per Day</title>
        <time_frame>From week 4 (baseline for re-randomization phase) to week 10 (end of re-randomization phase)</time_frame>
        <population>The mITT population for Re-randomization and Observational Phases consisted of all patients who were re-randomized, received at least one dose of Lantus after re-randomization, and had both a re-randomization baseline assessment and at least one post re-randomization assessment of FPG.</population>
        <group_list>
          <group group_id="O1">
            <title>SoloSTAR® Pen</title>
            <description>Patients randomized to SoloSTAR® Pen during the Re-randomization period (Week 4 to Week 10)</description>
          </group>
          <group group_id="O2">
            <title>Vial and Syringe</title>
            <description>Patients randomized to Vial and Syringe during the Re-randomization period (Week 4 to Week 10)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lantus Dose Injected Per Day</title>
          <population>The mITT population for Re-randomization and Observational Phases consisted of all patients who were re-randomized, received at least one dose of Lantus after re-randomization, and had both a re-randomization baseline assessment and at least one post re-randomization assessment of FPG.</population>
          <units>U (insulin unit)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.361" spread="0.786"/>
                    <measurement group_id="O2" value="6.336" spread="0.796"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving HbA1c Goal</title>
        <description>Percentage of patients achieving HbA1c &lt; 7% at Week 40 (end of the observational phase)</description>
        <time_frame>measured at week 40 or at study discontinuation</time_frame>
        <population>Patients from the mITT population for Re-randomization and Observational Phases who had at least one post re-randomization assessment of HbA1c.</population>
        <group_list>
          <group group_id="O1">
            <title>SoloSTAR® Pen</title>
            <description>Patients randomized to SoloSTAR® Pen during the Re-randomization phase (from Week 4 to Week 10) and the Observational phase (from Week 10 to Week 40).</description>
          </group>
          <group group_id="O2">
            <title>Vial and Syringe</title>
            <description>Patients randomized to Vial and Syringe during the Re-randomization phase (from Week 4 to Week 10) and the Observational phase (from Week 10 to Week 40).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving HbA1c Goal</title>
          <description>Percentage of patients achieving HbA1c &lt; 7% at Week 40 (end of the observational phase)</description>
          <population>Patients from the mITT population for Re-randomization and Observational Phases who had at least one post re-randomization assessment of HbA1c.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.7"/>
                    <measurement group_id="O2" value="37.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Observation of HbA1c &lt;7%</title>
        <time_frame>From week 10 to week 40 (observational phase)</time_frame>
        <population>The mITT population for Re-randomization and Observational Phases consisted of all patients who were re-randomized, received at least one dose of Lantus after re-randomization, and had both a re-randomization baseline assessment and at least one post re-randomization assessment of HbA1c.</population>
        <group_list>
          <group group_id="O1">
            <title>SoloSTAR® Pen</title>
            <description>Patients randomized to SoloSTAR® Pen during the Re-randomization phase (from Week 4 to Week 10) and the Observational phase (from Week 10 to Week 40).</description>
          </group>
          <group group_id="O2">
            <title>Vial and Syringe</title>
            <description>Patients randomized to Vial and Syringe during the Re-randomization phase (from Week 4 to Week 10) and the Observational phase (from Week 10 to Week 40).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Observation of HbA1c &lt;7%</title>
          <population>The mITT population for Re-randomization and Observational Phases consisted of all patients who were re-randomized, received at least one dose of Lantus after re-randomization, and had both a re-randomization baseline assessment and at least one post re-randomization assessment of HbA1c.</population>
          <units>Days since Re-randomization (week 4)</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166" lower_limit="88" upper_limit="248"/>
                    <measurement group_id="O2" value="168" lower_limit="91" upper_limit="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Discontinued Investigational Product (IP) During the Crossover Phase</title>
        <time_frame>From baseline to week 4 (crossover phase)</time_frame>
        <population>Randomized population (crossover phase) exposed to at least one dose of the IP</population>
        <group_list>
          <group group_id="O1">
            <title>SoloSTAR® Pen (Period 1)</title>
            <description>Patients using SoloSTAR® pen during period 1 of the crossover phase.</description>
          </group>
          <group group_id="O2">
            <title>Vial and Syringe (Period 2)</title>
            <description>Patients using Vial and Syringe during period 2 of the crossover phase.</description>
          </group>
          <group group_id="O3">
            <title>SoloSTAR® Pen (Period 2)</title>
            <description>Patients using SoloSTAR® pen during period 2 of the crossover phase.</description>
          </group>
          <group group_id="O4">
            <title>Vial and Syringe (Period 1)</title>
            <description>Patients using Vial and Syringe during period 1 of the crossover phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Discontinued Investigational Product (IP) During the Crossover Phase</title>
          <population>Randomized population (crossover phase) exposed to at least one dose of the IP</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="194"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49"/>
                    <measurement group_id="O2" value="2.01"/>
                    <measurement group_id="O3" value="3.09"/>
                    <measurement group_id="O4" value="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Discontinued Investigational Product During the Re-randomization Phase</title>
        <time_frame>From week 4 to week 10 (re-randomization phase)</time_frame>
        <population>Re-randomized population at week 4 exposed to at least one dose of the IP</population>
        <group_list>
          <group group_id="O1">
            <title>SoloSTAR® Pen</title>
            <description>Patients using SoloSTAR® pen during the re-randomization phase.</description>
          </group>
          <group group_id="O2">
            <title>Vial and Syringe</title>
            <description>Patients using Vial and Syringe during the re-randomization phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Discontinued Investigational Product During the Re-randomization Phase</title>
          <population>Re-randomized population at week 4 exposed to at least one dose of the IP</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6"/>
                    <measurement group_id="O2" value="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Discontinued Investigational Product During the Observational Phase</title>
        <time_frame>From week 10 to week 40 (observational phase)</time_frame>
        <population>Re-randomized population at week 4 and included in the observational phase at week 10 and exposed to at least one dose of the IP</population>
        <group_list>
          <group group_id="O1">
            <title>SoloSTAR® Pen</title>
            <description>Patients using SoloSTAR® pen during the observational phase.</description>
          </group>
          <group group_id="O2">
            <title>Vial and Syringe</title>
            <description>Patients using Vial and Syringe during the observational phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Discontinued Investigational Product During the Observational Phase</title>
          <population>Re-randomized population at week 4 and included in the observational phase at week 10 and exposed to at least one dose of the IP</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                    <measurement group_id="O2" value="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients With Hypoglycemic Events</title>
        <description>The hypoglycemic event was to be recorded on the electronic case report form hypoglycemia page and had to fit in one of the following categories: Mild-to-moderate hypoglycemia (36 mg/dL ≤ Self Monitored Blood Glucose (SMBG) &lt;70mg/dL), Severe hypoglycemia (assistance of another person is required, and either a recorded SMBG &lt;36 mg/dL, or treatment with oral carbohydrates, intravenous glucose or glucagon with prompt response) or Hypoglycemia symptoms with or without SMBG values with a documented SMBG &gt;70 mg/dL, or no recorded SMBG value. Only hypoglycemia events associated with coma, loss of consciousness or seizure were considered serious adverse event (SAEs).</description>
        <time_frame>each study phase (crossover, re-randomization, observational) up to 40 weeks</time_frame>
        <population>The safety population for each phase (crossover, re-randomization, observational) was the total treated population defined as all the patients who were randomized and exposed to at least one dose of Lantus during that phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Crossover Phase: SoloSTAR® Pen</title>
            <description>Patients using the SoloSTAR® Pen during the crossover phase either at period 1 or at period 2 depending on the sequence allocated by randomization.</description>
          </group>
          <group group_id="O2">
            <title>Crossover Phase: Vial and Syringe</title>
            <description>Patients using Vial and Syringe during the crossover phase either at period 1 or at period 2 depending on the sequence allocated by randomization.</description>
          </group>
          <group group_id="O3">
            <title>Re-randomization Phase: SoloSTAR® Pen</title>
            <description>Patients randomized to SoloSTAR® Pen during the Re-randomization period (Week 4 to Week 10)</description>
          </group>
          <group group_id="O4">
            <title>Re-randomization Phase: Vial and Syringe</title>
            <description>Patients randomized to Vial and Syringe during the Re-randomization period (Week 4 to Week 10)</description>
          </group>
          <group group_id="O5">
            <title>Observational Phase: SoloSTAR® Pen</title>
            <description>Patients using SoloSTAR® Pen during the Observational phase (from Week 10 to Week 40)</description>
          </group>
          <group group_id="O6">
            <title>Observational Phase: Vial and Syringe</title>
            <description>Patients using Vial and Syringe during the Observational phase (from Week 10 to Week 40)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Hypoglycemic Events</title>
          <description>The hypoglycemic event was to be recorded on the electronic case report form hypoglycemia page and had to fit in one of the following categories: Mild-to-moderate hypoglycemia (36 mg/dL ≤ Self Monitored Blood Glucose (SMBG) &lt;70mg/dL), Severe hypoglycemia (assistance of another person is required, and either a recorded SMBG &lt;36 mg/dL, or treatment with oral carbohydrates, intravenous glucose or glucagon with prompt response) or Hypoglycemia symptoms with or without SMBG values with a documented SMBG &gt;70 mg/dL, or no recorded SMBG value. Only hypoglycemia events associated with coma, loss of consciousness or seizure were considered serious adverse event (SAEs).</description>
          <population>The safety population for each phase (crossover, re-randomization, observational) was the total treated population defined as all the patients who were randomized and exposed to at least one dose of Lantus during that phase.</population>
          <units>participants having reported the event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="396"/>
                <count group_id="O2" value="399"/>
                <count group_id="O3" value="165"/>
                <count group_id="O4" value="165"/>
                <count group_id="O5" value="159"/>
                <count group_id="O6" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hypoglycemic event with or without SMBG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="48"/>
                    <measurement group_id="O5" value="76"/>
                    <measurement group_id="O6" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycemia with SMBG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="81"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="47"/>
                    <measurement group_id="O5" value="75"/>
                    <measurement group_id="O6" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptomatic hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="37"/>
                    <measurement group_id="O5" value="61"/>
                    <measurement group_id="O6" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycemia, assistance required</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The median of exposure to each device was 14 days during the crossover phase. The median of exposure was 43 days in both arms during the re-randomization phase. During the observational phase, it was 209 days in the pen arm and 210 days in the vial arm.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Crossover Phase: SoloSTAR® Pen</title>
          <description>Patients using the SoloSTAR® Pen during the crossover phase either at period 1 or at period 2 depending on the sequence allocated by randomization.</description>
        </group>
        <group group_id="E2">
          <title>Crossover Phase: Vial and Syringe</title>
          <description>Patients using Vial and Syringe during the crossover phase either at period 1 or at period 2 depending on the sequence allocated by randomization.</description>
        </group>
        <group group_id="E3">
          <title>Re-randomization Phase: SoloSTAR® Pen</title>
          <description>Patients randomized to SoloSTAR® Pen during the Re-randomization period (Week 4 to Week 10)</description>
        </group>
        <group group_id="E4">
          <title>Re-randomization Phase: Vial and Syringe</title>
          <description>Patients randomized to Vial and Syringe during the Re-randomization period (Week 4 to Week 10)</description>
        </group>
        <group group_id="E5">
          <title>Observational Phase: SoloSTAR® Pen</title>
          <description>Patients using SoloSTAR® Pen during the Observational phase (from Week 10 to Week 40)</description>
        </group>
        <group group_id="E6">
          <title>Observational Phase: Vial and Syringe</title>
          <description>Patients using Vial and Syringe during the Observational phase (from Week 10 to Week 40)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Cauda equina syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pancreatic mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar I disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast calcifications</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Transurethral bladder resection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Urethral obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="35" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="34" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="399"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Trial Transparency Team</name_or_title>
      <organization>Sanofi</organization>
      <email>Contact-US@sanofi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

